about
Surgery of primary melanomas.Clinical relevance of melanoma micrometastases (<0.1 mm) in sentinel nodes: are these nodes to be considered negative?Morbidity and prognosis after therapeutic lymph node dissections for malignant melanoma.Extra-axial chordoma.Multivariable analysis comparing outcome after sentinel node biopsy or therapeutic lymph node dissection in patients with melanoma.Gamma probe and ultrasound guided fine needle aspiration cytology of the sentinel node (GULF) trial - overview of the literature, pilot and study protocol.Therapeutic surgical management of palpable melanoma groin metastases: superficial or combined superficial and deep groin lymph node dissection.Molecular characterization and patient outcome of melanoma nodal metastases and an unknown primary site.The prognostic significance of sentinel node tumour burden in melanoma patients: an international, multicenter study of 1539 sentinel node-positive melanoma patients.Conditional survival of malignant melanoma in The Netherlands: 1994-2008.Pigmentation in the sentinel node correlates with increased sentinel node tumor burden in melanoma patients.[Sonographic criteria for diagnosing sentinel node metastases in melanoma patients].Risk Factors for Positive Deep Pelvic Nodal Involvement in Patients with Palpable Groin Melanoma Metastases: Can the Extent of Surgery be Safely Minimized? : A Retrospective, Multicenter Cohort Study.(Near-Infrared) Fluorescence-Guided Surgery Under Ambient Light Conditions: A Next Step to Embedment of the Technology in Clinical RoutineEfficacy of isolated limb perfusion (ILP) in patients with Merkel cell carcinoma (MCC): A multicenter experience.Clinical prognostic markers in stage IIIC melanoma.Sentinel node biopsy in melanoma: Current controversies addressed.Timing of completion lymphadenectomy after positive sentinel node biopsy in patients with melanoma.Isolated Limb Perfusion for Melanoma is Safe and Effective in Elderly Patients.Unknown Primary Melanoma: Worldwide Survey on Clinical Management.Implementation of the 7th edition AJCC staging system: Effects on staging and survival for pT1 melanoma. A Dutch population based study.Clinical Prognostic Markers in Stage IIIB Melanoma.Effects of time interval between primary melanoma excision and sentinel node biopsy on positivity rate and survival.The interval between primary melanoma excision and sentinel node biopsy is not associated with survival in sentinel node positive patients - An EORTC Melanoma Group study.Erratum to: gamma probe and ultrasound guided fine needle aspiration cytology of the sentinel node (GULF) trial - overview of the literature, pilot and study protocol.Cutaneous melanoma and sentinel lymph node biopsy.EORTC Melanoma Group sentinel node protocol identifies high rate of submicrometastases according to Rotterdam Criteria.Response to Wheatley et al., "Surgical excision margins in primary cutaneous melanoma: A meta-analysis and Bayesian probability evaluation", Cancer Treatment Reviews.Positron emission tomography/computed tomography evaluation of oncolytic virus therapy efficacy in melanoma.The analysis of the outcomes and factors related to iliac-obturator involvement in cutaneous melanoma patients after lymph node dissection due to positive sentinel lymph node biopsy or clinically detected inguinal metastases.Improved stratification of pT1 melanoma according to the 8th American Joint Committee on Cancer staging edition criteria: A Dutch population-based study.Optimal extent of completion lymphadenectomy for patients with melanoma and a positive sentinel node in the groin.Isolated limb perfusion for locally advanced angiosarcoma in extremities: A multi-centre study.The Diagnostic Value of PET/CT Imaging in Melanoma Groin Metastases.Remarkable effects of imatinib in a family with young onset gastrointestinal stromal tumors and cutaneous hyperpigmentation associated with a germline KIT-Trp557Arg mutation: case report and literature overview.PET/CT surveillance detects asymptomatic recurrences in stage IIIB and IIIC melanoma patients: a prospective cohort study.Immediate completion lymph node dissection in stage IIIA melanoma does not provide significant additional staging information beyond EORTC SN tumour burden criteria.Pre-SN Ultrasound-FNAC can be Sensitive for Lymph Node Metastases in Melanoma Patients if Performed with the Use of the Berlin Criteria.Comment: Detailed Pathologic Examination of Completion Node Dissection Specimens and Outcome for Melanoma Patients with Minimal (< 0.1 mm) Sentinel Lymph Node Metastases.Blue dye can be safely omitted in most sentinel node procedures for melanoma.
P50
Q30356095-68DE9C69-6DAB-484C-88F6-E4A359064FDFQ33257325-E0570EDC-278F-40C6-9F18-67023C976E96Q33266176-8CA22BBF-CD58-4A68-8E51-7BAE1E1A72A5Q33272662-ED29EB28-32EE-474F-9314-3918238C5BC5Q33294306-12989DAE-04C1-4BCF-B8A5-42F1576D4C33Q33556234-45F8317F-E956-49E9-9725-0B248A2607F7Q33888068-3F6CFF4D-729F-4865-A937-88DA89337332Q34446657-5132A9F2-07D1-44FF-BDBE-954589D2C71AQ35001487-EF36A316-F177-494D-95EA-A4C53CF3D958Q35049987-176986E4-5044-466B-9C25-B037D809ECF7Q35114518-6A4FABE2-7C0E-453B-9B22-9CC78E399C32Q35157317-C17E0D76-F368-48F1-B964-21767D120A86Q36391793-727AA6CF-F356-44D2-A3E1-5293E182E787Q37053431-A72377C2-3704-4925-8D1A-8A750893F1AAQ38627602-83573482-B533-4B1A-AD87-C11AE36F9A65Q38730176-19F3F81E-6387-4A37-9806-E7B009586956Q38945283-76230E45-7C65-43DA-9096-8B7D7532BDA3Q38951984-636AE9C8-F06A-4813-97F1-DAE2D84C582AQ38966445-3702579B-427F-4FE6-99F8-25EFFECD5640Q39067154-FAC62165-E41E-46F6-96D7-77FA4BA93172Q40370424-960F134D-9763-44E3-903C-8CCE40715329Q40499009-5903D301-3EEA-4011-8D67-C56AC0B6D04FQ40565521-BA6C568C-156D-48AF-BD60-42D0004F6202Q40717029-08C7A151-3CFF-4186-950F-76BFCE3DC067Q42344792-2492145C-6584-434F-8CB9-F1644D558508Q43215428-7E639AF6-6D32-47B9-8B7E-C006B4BAD6E7Q44390682-CC8637C9-C5B2-4E3D-9829-B6B165E58A21Q44576925-788E507C-04E7-4235-9BBB-A6440D14DCA3Q45323565-D93B02DC-6F84-4ABB-8598-73FE3E793D3FQ45851021-D6EDFC0D-97FE-4562-AC1E-AAC0ED772804Q47348659-F8657A07-C991-498B-B0D8-22E617359C2BQ47669815-5483B046-CC2B-403C-887A-246981A28423Q47791097-B155653C-0254-4498-A15E-D25F140E43C9Q47873511-389F4A68-95A7-4CE0-B1E6-6F75BC549583Q48121674-D61090CF-924A-453A-8BC8-A990A9484136Q48824408-F17AD9D7-5DE9-4F7E-B6AA-B87915B3E6B5Q49550293-8E723C8E-0372-41F1-81E1-F97D0824B7D2Q49843707-DB57AD60-CE9A-4960-8AF2-9D5C1C9221B4Q50108588-00990FAF-2CA3-4C76-A4CE-7532BACE2C66Q50201619-75D837E9-30A4-412C-891C-FF0552596176
P50
description
researcher ORCID ID = 0000-0002-3262-6935
@en
wetenschapper
@nl
name
Alexander C.J. van Akkooi
@ast
Alexander C.J. van Akkooi
@en
Alexander C.J. van Akkooi
@es
Alexander C.J. van Akkooi
@nl
type
label
Alexander C.J. van Akkooi
@ast
Alexander C.J. van Akkooi
@en
Alexander C.J. van Akkooi
@es
Alexander C.J. van Akkooi
@nl
prefLabel
Alexander C.J. van Akkooi
@ast
Alexander C.J. van Akkooi
@en
Alexander C.J. van Akkooi
@es
Alexander C.J. van Akkooi
@nl
P108
P1153
11840468000
P31
P496
0000-0002-3262-6935